NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ:MGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Metagenomi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On or around February 12, 2024, Metagenomi conducted its initial public offering, selling approximately 6.25 million shares priced at $15.00 per share.
Then, on May 1, 2024, Metagenomi announced that it and Moderna, Inc. had "mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1)," and that the "rights to develop the PH1 pro-gram, as well as all other rights granted under the collaboration, will be returned [to Metagenomi] as part of the termination."
On this news, Metagenomi's stock price fell $0.87 per share, or 12.36%, to close at $6.17 per share on May 2, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP
View the original
press release on accesswire.com
